Hepatitis C virus (HCV) infection becomes a major public health problem and leading cause of chronic liver disease and liver failure. Pegylated interferon-alfa and ribavirin are currently the standard treatment for chronic hepatitis C (CHC). It is indicated that genes that trace the interferon signaling could be associated with the host response to the therapy.
Introduction
Hepatitis C Virus (HCV) infection is arising as global health problem with more than 177 million people affected worldwide or 2.5% of the population (1) . Acute HCV infection is mainly asymptomatic, but with a time it is leading to persistent HCV infection associated with the development of liver cirrhosis, hepatic cancer, liver failure, and death (2) . Hepatitis C virus (HCV) is genetically highly diverse, displaying regional variations in genotype prevalence. Genotypes 1 and 3 dominate in most countries, while less frequent are genotypes 2, 4, 5 and 6 (3). Today, the standard treatment for HCV infection, accepted worldwide, includes a combination of pegylated interferon (PEG-IFN-α) and ribavirin -RBV (4) . This therapy is introduced in the Republic of Macedonia in 2006. Administration of this therapy is physically and economically highly demanding, but with low success rate and highly dependable on HCV genotype (5) . A sustained virological response (SVR) is achieved in only a half of genotype 1-infected patients, genotype 4 is also resistant to IFN-α therapy, while higher success rate can be achieved in treatment of patients with genotypes 2 and 3 (6) . Furthermore, this therapy is associated with considerable toxicity and various side effects (flu-like syndrome or hematologic abnormalities), often requiring a dose reduction. In more than 15% a discontinuation in administration of the therapy is needed (7, 8) . Therefore, the prediction of a patient's response before the treatment is of great clinical importance for avoiding the side effects of the therapy as well as to prevent the cost of treatment in those patients that do not respond.
The treatment outcome is associated with several viral and host factors such as viral load, obesity, age, male sex, ethnicity or genotypes (9, 10) . The rate of HCV-RNA decline during treatment and virological responses at week 4 (rapid virologic response -RVR) and week 12 (early virologic response-EVR) are predictive factors of the treatment as well (11, 12) .
Host genetic factors, mainly regulating the interferon metabolism have also been associated with the response to PEG-IFN-α /RBV therapy. Up to date, a number of candidate genes such as type 1 interferon receptor 1 (IFNAR1) (13) (20) have shown an association with treatment response and spontaneous clearance after HCV infection. IN28B or IFNL3 variant rs12979860 was proved to have a strong influence on host response to interferon therapy, with CC as a favorable response genotype and since 2014 it is recommended to be perform as a predictor of response to PEG-IFN-α /RBV containing regiment (21) .
The effective response and clearance of HCV is closely related to understanding interferon pathways and its downstream targeted genes. Many studies demonstrated that the polymorphisms in IFN signaling genes, including OASL gene, are related to a treatment response (22) (23) (24) . Oligoadenylate Synthase-Like Protein (OASL) with its 2'-5' oligoadenylate catalytic activity is recognized as a significant factor that influence antiviral response induced by the interferon (25, 26) . Interferon is proved as a molecule that regulates the early phase of viral infection by degrading viral RNA, and/or inhibition of viral replication (27) . The possibility that the host-related genetic variations imply the response rates of patients to IFN therapy is still in a field of research. In order to determine the influence of OASL polymorphisms on patient's viral response, seven single nucleotide polymorphisms (SNP) in this gene were investigated (rs59248852, rs74390571, rs12811390, rs1169279, rs3213545, rs1083129 and rs2859398). For that purpose, a new fast and reliable SNaPshot method for simultaneous determination of these polymorphisms was introduced.
Materials and Methods

Patient samples
This study was conducted on 209 HCV RNA positive patients included in the program of supplemental therapy with pegylated interferon / ribavirin (Pegasys ® , Hofman La Roche) in a period of 24 Peripheral blood samples were collected and genomic DNA was extracted using Proteinase K digestion, phenol/chloroform extraction and ethanol precipitation method. The concentration and purity of isolated DNA samples was determined using NanoVue-UV/VIS spectrophotometer (GE Healthcare, Little Chalfont, UK).
Detection and Quantification of HCV RNA
HCV RNA detection and quantification was performed using AMPLICOR HCV v2.0 kit (Roche Molecular Diagnostics, Pleasanton, CA). All operational steps were carried out according to the instructions given in the manuals provided by the manufacturer. The lower limit of detection of AMPLICOR HCV v2.0 was 50 IU ml (28) .
Multiplex SNaPshot method for detection of 7 polymorphisms in OASL gene
The variant types of 7 different polymorphisms in OASL gene: rs59248852, rs74390571, rs12811390, rs1169279, rs3213545, rs1083129 and rs2859398 were analyzed using the primer extension-based method or SNaPshot. Typing of seven different polymorphisms in the OASL gene was done by two multiplex PCR reactions for each patient. The first reaction included polymorphisms (rs2859398, rs1083129, rs74390571 and rs59248852), while the second one encompassed the remaining three ( Table 1) . Briefly, the first PCR amplification was conducted in total volume of 20 μL containing: 0.5 μg genomic DNA, buffer (50 mM Tris-HCl, pH 9.2, 16 mM (NH4) 2 SO4, 0.1% Tween 20), 4.0 pmol of specific primers, 200 μM mix of each dNTP, 1.75 mM MgCl 2 , and 0.5U of enzyme Tth DNA polymerase. The PCR conditions were as follows: 2 min initial denaturation, 10 cycles of denaturation for 15 sec at 95°C, annealing 30 sec at 60°C, and elongation 3 min at 68°C, followed by 25 cycles of 15 sec at 95°C, annealing 30 sec at 60°C, and elongation 3 min at 68°C plus 5 second at each cycle, and final extension was at 68°C for 7 min. The final PCR product was 3 kb.
The second PCR amplification reaction contained 0.1-0.5 μg genomic DNA, 10xB2 buffer (Solis BioDyne, Tartu Estonia), 4.0 pmol of specific oligonucleotide primers, 200 μM dNTPs, 2.5 mM MgCl 2 , and 0.4U Hot Firepol DNA polymerase (Solis BioDyne, Tartu Estonia) in a total volume of 20 μl. The PCR conditions were as follows: 10 min initial denaturation, 38 cycles of 95°C for 30 sec, 60°C for 45 sec, 72°C for 1 min, and final extension was at 72°C for 5 min. Three PCR products were obtained: 150, 117 and 367 bp. ExoSAP-IT (USB, Cleveland, OH) was used for purifying the PCR products at at 37°C for 60 min followed by 86°C for 15 min for deactivation of the enzyme.
The SNaPshot PCR reaction was performed in multiplex format by adding specific primers for each polymorphism in concentration of 1 pM each ( Table 2 ). The reaction was performed on a thermal cycler using the following conditions: 25 cycles of 95°C for 10 s, 55°C for 5 s, and 60°C for 30 s. The SNaPshot reaction was cleaned up with one unit of Shrimp alkaline phosphatase (SAP; GE Healthcare) for an hour at 37 o C, followed by capillary electrophoresis on 3500 Genetic analyzer using GeneMapper Software Version 4.0 (Life Technologies). 0.5 µl GeneScan120 LIZ was used as a Size Standard ladder (Life Technologies Corporation, Carlsbad, CA, USA). The representative electrophoretic pattern for the seven analyzed OASL polymorphisms is given in Fig. 1 .
Direct sequencing was used as a gold standard in order to optimize and validate the SNaPhot assay. Genomic DNA from 10 CHC patients, with previously determined OASL gene polymorphisms, was sequenced using BigDye terminator cycle sequencing reaction kit v1.1 (Applied Biosystems, Foster City, CA) and the same forward and reverse primers ( Table 1) . The amplified products were purified using 1-step enzymatic PCR and clean up system -Illustra ExoStar 1-step kit (GE Healthcare, Life Science, Little Chalfont, UK). Capillary electrophoresis was conducted on an ABI Prism 3130 Genetic analyzer (Life Technologies, USA), according the manufacturer protocol. Data were analyzed using GeneMapper analysis software version 4.0. These samples were also used to determine the reproducibility and performance (specificity and sensitivity) of the single-nucleotide primer extension method. 
Results
In order to determine their association with the host's response to Peg-IFN-α plus ribavirin therapy in CHC patients, seven single nucleotide polymorphisms (rs59248852, rs74390571, rs12811390, rs1169279, rs3213545, rs1083129 and rs2859398) in OASL gene were analyzed using a multiplex SNaPshot method. A total of 209 CHC patients on pegylated interferon / ribavirin therapy of 24 / 48 weeks (for patients with genotype 3 / genotype 1, respectively) were included in the study. Patients who were negative for viral RNA at fourth week of therapy were considered with rapid virological response (RVR). Patients who showed no decline of the viral load after twelve weeks of treat- ment or who remained HCV-RNA positive at week 24 were considered as non-responders (NVR). The sustained virological response (SVR) was obtained if a patient remains negative 24 weeks after ending therapy. Patients included in this study were separated in two groups: 100 patients without response to antiviral therapy (NVR) and 109 cases with sustained viral response (SVR). In the group of NVR, 21 patients were genotype 3 and 79 patients were with genotype 1, while in the group with SVR, 73 patients were genotype 3 and 36 patients with HCV genotype 1. The validation of the assay was carried out on 10 DNA samples with OASL gene polymorphisms previously determined with SNaPshot method, demonstrating that it could accurately detect the 7 tested OASL gene polymorphisms ( Table 3) . Our results showed 100% concordance with the Sanger sequencing method confirming that the new assay was highly accurate. Reproducibility of the assay was ascertained by testing one sample in triplicate.
Allele frequencies distribution in both NVR and SVR patients groups for all the analyzed SNP's are presented in Table 4 . Genotype frequencies for all analyzed SNP's together with the results from dominant and recessive genetic models used for comparison between NVR and SVR patients groups are presented in Table 5 . , OR=3.4 (2.2-5.0)]. For two SNP`s (rs1169279 and rs3213545) we didn't find any significant association between the analyzed groups. Comparison of OASL allele frequencies between NVR and SVR patients is shown in Fig. 2 . Alleles rs59248852-T, rs74390571-A, rs12811390-A, rs1083129-A and rs2859398-C were more common in the group of patients with SVR in comparison to those who did not respond to the standard therapy.
Analyzing genotype distribution in rs59248852 polymorphism we found TT genotype in only 2% of analyzed NVR patients, while 50.46% of patients in SVR group have TT genotype. Statistical analysis indicated that patients with TT genotype for the rs59248852 polymorphism have almost 50 times higher chances to respond to the interferon therapy than CC or CT genotypes [p=3.9x10 -15 ; OR (95%CI)= 49.9 (11.8-212.6)]. Genotype distribution of rs74390571 polymorphism shows AA genotype in seven patients (7%) of NVR group, and 26 (23.85%) patients in SVR group. Statistical analysis indicated that patients with AA genotype for the rs74390571 polymorphism have 4.2 times higher chances to respond to the interferon therapy than GG or GA genotypes [p= 0.0008; OR (95%CI)= 4. In stepwise logistic regression analysis we have included the genotype data for seven studied polymorphisms (homozygous genotypes for major alleles as references) and HCV genotype (G1 genotype as a reference) when building the model for prediction of the SVR outcome (NVR as a reference) ( Table 6 ). The model retained 4 (rs59248852, rs74390571, rs12811390 and rs2859398) out of 7 studied SNPs as predictors. The p value for the Hosmer and Lemeshow test at final step was p=0.8791, suggesting that the model is a good fit to the data. When the classification cut-off was set at 0.6, the model correctly classified the outcome in 84.6% of the cases.
Discussion
Seven single nucleotide polymorphisms (rs59248852, rs74390571, rs12811390, rs1169279, rs3213545, rs1083129 and rs2859398) in OASL gene were analyzed in two groups of CHC patients (NVR and SVR) in order to determine their influence on host response to Peg-IFN-α and RBV therapy. For that purpose a multiplex SNaPshot method was introduced. It is accurate, simply to perform, cost effective and time consuming in comparison with PCR-RFLP or dot blot hybridization.
Of the seven SNP's evaluated, a clear statistical association was found in five of them. A strong significant association was determined in four: rs59248852, rs74390571, rs12811390 and rs2859398 (p=6.5x10 -31 , p=4.3x10 -7 , p=2.2x10 -11 and p=1.34x10 -9 respectively), while in one rs1083129, a significant association was found with p=0.0139. The rs59248852-T allele, rs74390571-A allele, rs12811390-A allele, rs1083129-A allele and rs2859398-C allele were significantly associated with obtaining SVR after interferon administered therapy ( Table 5 ). The logistic regression showed that SNPs with strong significant association for SVR analyzed with the genotype test (Table 5) were also significant predictors for SVR when analyzed together ( Table 6) .
With this study we confirm the previous reports that polymorphisms in OASL gene could be host related factors that determine the success rate of the interferon therapy. The human OAS family is located on 12q24.1 region on chromosome 12. It consists of four genes: OAS1, OAS2, OAS3 and OASL gene. It is already defined that some single nucleotide polymorphisms (SNPs) in this genes have influence on the host response to administered interferon-based therapy in patients infected with HCV. Su et al. in 2008 (20) found three OASL SNPs (rs2859398; rs3213545; rs1169279) to be associated with sustained virological response and they suggested the possible mechanism of the influence of these polymorphisms on the response to interferon therapy. For example they speculate that change in the sequence C/T in rs3213545, leads to change in SF2/AFF consensus ESE site, thus leading to reduction of the amount of full-length transcripts of the corresponding proteins. Their explanation was that the carrier of the mutant allele for those SNPs may have lower expression of OASL gene as compared with normal allele carriers, a condition that lead to increased antiviral activity of OAS isozymic forms, and viral clearance (29) .
Other studies also indicate the influence of OASL gene polymorphisms on the outcome of interferon therapy. Yakub et al. 2005 analyzing the influence of 23 SNP's in OASL gene on outcome of therapy in patients infected with West Nile Virus infection, also identified a strong relationship between SNP rs3213545 and susceptibility to severe WNV disease (30) (31) (32) . In the cohort of 23 analyzed SNP's that Yakub included in his study was a rs3213545, and supporting our results, he also did not found an association between this SNP and the outcome of the administered therapy. Domagalski et al. analyzing the influence of IL28B and OAS polymorphisms, find an association between OASL gene polymorphism (rs1083129) and response to interferon therapy in pediatric cases with Hepatitis B infection (33) .
The prediction of an individual's response before the treatment is of great clinical importance for avoiding the side effects of the therapy as well as the substantial cost of PEG-IFN-α / RBV treatment in those patients that do not respond. The results of this study suggest that CHC patients with HCV Genotype 3 and OASL polymorphisms rs59248852 -T/T, rs74390571 -A/A, rs12811390 A/A and rs2859398 -C/C are significantly associated with SVR and might be used as predictors for successful administration of interferon therapy.
In conclusion, an inexpensive multiplex SNaPshot method was introduced for rapid determination of OASL polymorphisms that can be used as predictive factors of patient's response to the standard interferon therapy still used in many developing countries, thus having an important cost benefit for their health insurance systems.
